How to Help Your Patients Save Money on Bexagliflozin (Brenzavvy): A Provider's Guide to Savings Programs

Bexagliflozin (Brenzavvy) was designed from the ground up to be affordable. At approximately $47–$50/month through partner pharmacies, it is the lowest-cost SGLT2 inhibitor available in the US. Yet despite this pricing advantage, many patients still struggle to access it due to unfamiliarity with non-traditional pharmacy channels. This guide gives prescribers the tools to help every patient access Brenzavvy at the lowest possible cost.

Understanding Brenzavvy's Unique Pricing Model

Unlike Jardiance or Farxiga, bexagliflozin does not have a traditional manufacturer savings card, copay card, or patient assistance program (PAP). Instead, TheracosBio has taken a different approach: pricing the drug at approximately $50/month at launch and distributing it through low-overhead pharmacy partners.

This has important implications for patient counseling:

There is no income threshold for the low price — it is available to all patients

No enrollment forms, copay card activations, or income documentation required

The savings are built in — the strategy is knowing which pharmacy to use

Pharmacy-by-Pharmacy Price Comparison

Here's what patients will pay for a 30-day supply of bexagliflozin 20 mg across different pharmacy channels in 2026:

DiRx (dirxhealth.com): $47.75/month — lowest known price

Cost Plus Drugs (costplusdrugs.com): $49.85/month; e-prescription directly from EHR

Marley Drug (marleydrug.com): ~$69/month; 90-day supply available

Publix (select locations): In-store pickup; price varies; call to confirm

IPC independent pharmacies: Pricing varies; can order through IPC network

Chain pharmacies (CVS, Walgreens) with SingleCare: ~$154/month — significantly higher than partner pharmacies

Retail list price (no discount): ~$400+/month

The Cash-Pay vs. Insurance Decision

For most patients, cash pay through a partner pharmacy will be cheaper than using insurance. Here's why:

Most commercial and Medicare plans don't include Brenzavvy on formulary

When covered, it's typically non-preferred brand — requiring PA and often resulting in a high copay

Cash pay through Cost Plus Drugs or DiRx removes the PA burden from your office and results in a lower out-of-pocket cost for the patient

Exception: Some PBMs (such as Scripius/Intermountain Health) have made Brenzavvy a preferred SGLT2 agent. If your patient's plan covers it as preferred, insurance may result in a lower cost. Encourage patients to check their formulary.

When Insurance Pursuit Makes Sense

Prior authorization pursuit is worthwhile in limited cases:

Patient's plan has listed Brenzavvy as a preferred SGLT2 agent (check formulary first)

Patient is unable to afford $47–$70/month for any reason

Patient has already failed or is contraindicated to preferred formulary SGLT2 agent (provides PA justification)

HSA/FSA Counseling for Patients

Remind patients with HSA or FSA accounts that prescription medications — including Brenzavvy — are eligible expenses. Paying through HSA/FSA effectively reduces the cost by their marginal tax rate. A patient in the 22% tax bracket paying $50/month with HSA funds has an effective out-of-pocket cost of about $39/month.

How to Streamline the Prescribing Process

To ensure your patients actually get their Brenzavvy and pay the lowest price:

At the point of prescribing, decide which pharmacy to use (Cost Plus Drugs or DiRx for most patients)

E-prescribe directly to the partner pharmacy — collect patient's email address

Inform the patient: "Your prescription has been sent to Cost Plus Drugs. You'll receive an email to complete your order. Expect delivery in 3–5 business days."

Instruct patient to reorder 7 days before running out to allow for shipping time

For local availability, direct patients to medfinder.com/providers to search pharmacy inventory in real time

Patient Populations Who Benefit Most

Uninsured or underinsured patients with type 2 diabetes who cannot afford Jardiance or Farxiga

Medicare patients in the Part D coverage gap who face high cost-sharing

High-deductible plan members who pay full drug cost until deductible is met

Patients who need only glycemic control (not heart failure or CKD outcomes benefit) and want the lowest cost option

For additional resources to help your patients find and afford their medications, visit medfinder.com/providers — a real-time pharmacy search tool built for healthcare providers.